- Home
- STTK vs FLL Comparison
STTK vs FLL Comparison
Compare STTK & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FLL
- Stock Information
- Founded
- STTK 2016
- FLL 1987
- Country
- STTK United States
- FLL United States
- Employees
- STTK N/A
- FLL N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- STTK Health Care
- FLL Consumer Discretionary
- Exchange
- STTK Nasdaq
- FLL Nasdaq
- Market Cap
- STTK 173.6M
- FLL 170.4M
- IPO Year
- STTK 2020
- FLL 1993
- Fundamental
- Price
- STTK $3.73
- FLL $5.03
- Analyst Decision
- STTK Strong Buy
- FLL Buy
- Analyst Count
- STTK 3
- FLL 2
- Target Price
- STTK $10.67
- FLL $6.50
- AVG Volume (30 Days)
- STTK 128.3K
- FLL 54.1K
- Earning Date
- STTK 11-07-2024
- FLL 11-06-2024
- Dividend Yield
- STTK N/A
- FLL N/A
- EPS Growth
- STTK N/A
- FLL N/A
- EPS
- STTK N/A
- FLL N/A
- Revenue
- STTK $4,123,999.00
- FLL $274,988,000.00
- Revenue This Year
- STTK $164.45
- FLL $26.61
- Revenue Next Year
- STTK N/A
- FLL $13.32
- P/E Ratio
- STTK N/A
- FLL N/A
- Revenue Growth
- STTK 380.09
- FLL 47.08
- 52 Week Low
- STTK $1.33
- FLL $3.40
- 52 Week High
- STTK $11.76
- FLL $5.98
- Technical
- Relative Strength Index (RSI)
- STTK 53.41
- FLL 51.44
- Support Level
- STTK $3.63
- FLL $4.85
- Resistance Level
- STTK $3.94
- FLL $5.14
- Average True Range (ATR)
- STTK 0.22
- FLL 0.15
- MACD
- STTK 0.06
- FLL 0.02
- Stochastic Oscillator
- STTK 64.91
- FLL 72.41
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.